Definition

An orally bioavailable inhibitor of various KRAS mutations, including the oncogenic KRAS substitution mutation G12D, with potential antineoplastic activity. Upon oral administration, KRAS mutant inhibitor QTX3034 targets, allosterically binds to and inhibits various forms of KRAS mutations, thereby inhibiting KRAS-dependent signaling. This inhibits the proliferation of and induces apoptosis in tumor cells in which KRAS is mutated. KRAS plays an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.